The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the ...

Check the time stamp on this data. Updated AI-Generated Signals for Biontech Se (BNTX) available here: BNTX. Type a few ...

Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to BioNTech SE (BNTX – Research Report). The ...

In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given ...

Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc ...

Fintel reports that on January 10, 2025, Truist Securities initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) with a Buy recommendation. Analyst Price Forecast Suggests 14.22% ...

Truist Financial initiated coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a ...

Key Insights Significant control over BioNTech by private equity firms implies that the general public has more ...